Live tape
Top 8, mentions 7d9,843TSLA2,036 mentions▲ +0.05GOOGL1,581 mentions▲ +0.04NVDA1,205 mentions▲ +0.07CRWV1,192 mentions▲ +0.03SPCX1,069 mentions▲ +0.07QQQ1,042 mentions▲ +0.04META873 mentions▲ +0.05NBIS845 mentions▲ +0.05

Equity · Healthcare

FDMT

NASDAQ

4D Molecular Therapeutics, Inc.

$10.98 −0.18% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for FDMT to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $759.5M
52-week range $4.16 – $13.32
Avg volume 193.5K

as of Jul 17, 2026

FDMT insider trades

SEC Form 4

FDMT has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 12 December 2025.

Date Insider Type Shares Value
17 Nov 2025 Bizily Scott Chief Legal Officer Sell 1,635 $17K
24 Oct 2025 Bizily Scott Chief Legal Officer Sell 2,678 $32K
16 Oct 2025 Bizily Scott Chief Legal Officer Sell 1,635 $17K
09 Oct 2025 Bizily Scott Chief Legal Officer Sell 2,408 $24K
23 Sep 2025 Bizily Scott Chief Legal Officer Sell 2,407 $19K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
12 Dec 2025 THEUER CHARLES Option exercise 9,333 $11K
09 Dec 2025 Humer Kristian Chief Financial Officer Award 480,000
17 Nov 2025 Bizily Scott Chief Legal Officer Option exercise 1,635 $7K
24 Oct 2025 Bizily Scott Chief Legal Officer Option exercise 1,084 $7K
16 Oct 2025 Bizily Scott Chief Legal Officer Option exercise 1,635 $7K

FDMT reported financials

SEC EDGAR XBRL SEC EDGAR

FDMT reported revenue of $85.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$140.1M.

Figure Reported Period
Revenue $85.2M 31 Dec 2025 fiscal year
Net income −$140.1M 31 Dec 2025 fiscal year
Diluted EPS −$2.42 31 Dec 2025 fiscal year
Total assets $492.6M 30 Jun 2026 at period end
Total equity $407.7M 30 Jun 2026 at period end

FDMT earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$1.04 $4M
31 Mar 2026 Q1 2026 −$1.01 $3M
31 Dec 2025 FY 2025 −$2.42 $85M
30 Sep 2025 Q3 2025 −$1.01 —
30 Jun 2025 Q2 2025 −$0.98 $0M
31 Mar 2025 Q1 2025 −$0.86 $0M
31 Dec 2024 FY 2024 −$2.98 $0M
30 Sep 2024 Q3 2024 −$0.79 $0M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

FDMT institutional holders

SEC Form 13F SEC EDGAR

8 of the 45 institutional funds we track reported a FDMT position for the quarter ended 30 Jun 2026 — a combined $21.6M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Citadel Advisors Added +160.4% shares 687,597 $9.1M
Renaissance Technologies Held (±25%) +6.3% shares 614,573 $8.2M
Two Sigma Investments Trimmed −44.1% shares 69,481 $924K
Man Group Added +135.8% shares 68,349 $909K
Fisher Asset Management New position 65,751 $874K
AQR Capital Management Held (±25%) +9.8% shares 50,281 $669K
D. E. Shaw & Co. Added +84.6% shares 44,354 $590K
Marshall Wace Added +27.6% shares 21,342 $284K

FDMT fails-to-deliver

SEC CNS data SEC

On 24 Sep 2026, 17,035 shares of FDMT failed to deliver (about $256K).

Settlement date Shares failed Notional % of shares out
24 Sep 2026 17,035 $256K 0.025%
18 Sep 2026 50,000 $734K 0.072%
10 Sep 2026 6 $85 <0.001%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings